Headlines from the Proactive UK newsroom.
Finland-based Faron Pharmaceuticals (LON:FARN) is going home and has applied to list on Nasdaq First North Growth Market, a multilateral trading facility in Helsinki. Trading is set to start on 3 December.
Oriole Resources (LON:ORR) has converted its interest in one of its Turkish assets to a 1.2% post-tax royalty. Oriole says the move will make it a valuable and potentially saleable asset.
Maxcyte (LON:MXCT) and oncology group Vor Biopharma have signed a clinical and commercial license agreement. Vor will use MaxCyte's technology to produce engineered stem cells.
Salt Lake Potash (LON:SO4) has inked a milestone native title agreement for its flagship Lake Way project in Western Australia. The agreement paves the way for the development to get underway.
Centrica (LON:CNA) continues to bleed energy supply customers, though the British gas owner says the rate of attrition is slowing. A net 107,000 switched off in the latest few months, though guidance on earnings, cash flow and net debt for 2019 is unchanged.
William Hill (LON:WMH) has closed 700 shops to offset the impact of the reduction of the fixed odds betting machines stake to £2. Good online growth is keeping the bookie on track even so with net revenue up 1% in the latest four weeks.
Royal Mail’s (LON:RMG) letter business is continuing to decline and will fall further despite the boost from the general election. Half year operating profits at the postie fell 13% even though revenues rose.